Lessons From MAVERICK-HCM
- 2 June 2020
- journal article
- editorial
- Published by Elsevier BV in Journal of the American College of Cardiology
- Vol. 75 (21), 2661-2663
- https://doi.org/10.1016/j.jacc.2020.04.017
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic CardiomyopathyJournal of the American College of Cardiology, 2020
- Myosin Sequestration Regulates Sarcomere Function, Cardiomyocyte Energetics, and Metabolism, Informing the Pathogenesis of Hypertrophic CardiomyopathyCirculation, 2020
- Mavacamten Treatment for Obstructive Hypertrophic CardiomyopathyAnnals of Internal Medicine, 2019
- Hypertrophic cardiomyopathy mutations in MYBPC3 dysregulate myosinScience Translational Medicine, 2019
- Genotype and Lifetime Burden of Disease in Hypertrophic CardiomyopathyCirculation, 2018
- Deciphering the super relaxed state of human β-cardiac myosin and the mode of action of mavacamten from myosin molecules to muscle fibersProceedings of the National Academy of Sciences of the United States of America, 2018
- Mavacamten stabilizes an autoinhibited state of two-headed cardiac myosinProceedings of the National Academy of Sciences of the United States of America, 2018
- Clinical Spectrum and Management of Heart Failure in Hypertrophic CardiomyopathyJACC: Heart Failure, 2018
- Effects of myosin variants on interacting-heads motif explain distinct hypertrophic and dilated cardiomyopathy phenotypeseLife, 2017
- A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in miceScience, 2016